|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS | ||||||||||||||||||||
| Prepaid expense | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Accounts payable and accrued liabilities (Note 4) | ||||||||||||||||||||
| Derivative liabilities (Note 8) | ||||||||||||||||||||
| Loan from a principal shareholder (Note 8) | ||||||||||||||||||||
| Promissory notes (Note 5) | ||||||||||||||||||||
| Convertible notes payable | ||||||||||||||||||||
| Convertible notes (Note 6) | ||||||||||||||||||||
| Interest payable on senior secured notes (Note 7) | ||||||||||||||||||||
| Long term convertible notes, net of discount | ||||||||||||||||||||
| Senior secured notes (Note 7) | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| MEZZANINE EQUITY | ||||||||||||||||||||
| Total Mezzanine Equity | ||||||||||||||||||||
| Series D Preferred Stock | ||||||||||||||||||||
| Series E One Preferred Stock | ||||||||||||||||||||
| Series H Preferred Stock | ||||||||||||||||||||
| STOCKHOLDERS’ DEFICIENCY | ||||||||||||||||||||
| Preferred Stock, Value, Issued | ||||||||||||||||||||
| Series D Preferred Stock | ||||||||||||||||||||
| Series E One Preferred Stock | ||||||||||||||||||||
| Series H Preferred Stock | ||||||||||||||||||||
| Common Stock - $0.001 par value; 6,000,000,000 shares authorized, 1,761,428,576 and 1,678,095,243 shares issued and outstanding, June 30, 2026 and December 31, 2025, respectively (Note 9) | ||||||||||||||||||||
| Additional Paid in Capital (Note 9) | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Series F Preferred Stock | ||||||||||||||||||||
| Total additional Paid in Capital (Note 9) | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ deficiency | ||||||||||||||||||||
| Total liabilities, mezzanine equity and stockholders’ deficiency | ||||||||||||||||||||
Loading...